Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Second-generation antipsychotic drugs (SGAs) are increasingly administered to achieve weight gain in anorexia nervosa. In this meta-analysis, we aimed to determine if any evidence for this treatment option can be derived from randomized controlled trials (RCTs). Methods: Based on the ‘World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders', a systematic update literature search was applied to identify all RCTs investigating the efficacy, acceptability, and tolerability of SGAs in anorexia nervosa in comparison to placebo/no treatment. The primary outcome was weight gain measured by mean change in body mass index (BMI). Secondary outcomes were mean changes in Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS) total score and Eating Disorders Inventory (EDI) total score and premature discontinuation of treatment. Employing a random-effects model standardized mean differences based on Hedges's g and Mantel-Haenszel risk ratios were calculated. Results: Seven RCTs (n = 201) investigating olanzapine (N = 4), quetiapine (N = 2), and risperidone (N = 1) were included. We found no statistically significant between-group differences for mean BMI change when pooling the SGAs (N = 7, n = 161; Hedges's g = 0.13, 95% CI: -0.17 to 0.43; p = 0.4) and when examining the individual drugs. Furthermore, the SGAs failed to differentiate statistically significantly from placebo/no treatment for all secondary outcomes. Conclusions: Based on the current evidence, pharmacological treatment of anorexia nervosa with SGAs cannot be generally recommended although some individuals or subgroups of patients might benefit from an antipsychotic medication. Further research is required to identify which patients will likely benefit from such a treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Neurobiology of anorexia and bulimia nervosa
Kaye, W. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.037 · Cited by 625
The epidemiology of eating disorders in six European countries: results of the ESEMeD-WMH project.
Preti, A., Girolamo, G. D., Vilagut, G., Alonso, J., Graaf, R. D., Bruffaerts, R., Demyttenaere, K., Pinto-Meza, A., Haro, J. M., & Morosini, P. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.04.003 · Cited by 456
Aigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
Olanzapine therapy in anorexia nervosa: psychobiological effects
Brambilla, F., Garcia, C. S., Fassino, S., Daga, G. A., Favaro, A., Santonastaso, P., Ramaciotti, C., Bondi, E., Mellado, C., Borriello, R., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328080ca31 · Cited by 156
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Mortality and predictors of death in a cohort of patients presenting to an eating disorders service
Button, E. J., Chadalavada, B., & Palmer, R. L. (2010) · International Journal of Eating Disorders · doi:10.1002/eat.20715 · Cited by 128
Mortality of eating disorders: a follow-up study of treatment in a specialist unit 1974-2000
Rosling, A. M., Sparén, P., Norring, C., & von Knorring, A. (2011) · International Journal of Eating Disorders · doi:10.1002/eat.20827 · Cited by 116
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Variation in results from randomized, controlled trials: stochastic or systematic?
Jane-wit, D., Horwitz, R. I., & Concato, J. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.02.010 · Cited by 33
Cited by
Treasure, J., Zipfel, S., Micali, N., Wade, T., Stice, E., Claudino, A., Schmidt, U., Frank, G. K., Bulik, C. M., & Wentz, E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.74 · Cited by 285
Self-citationTreatment of eating disorders: A systematic meta-review of meta-analyses and network meta-analyses
Monteleone, A. M., Pellegrino, F., Croatto, G., Carfagno, M., Hilbert, A., Treasure, J., Wade, T., Bulik, C. M., Zipfel, S., Hay, P., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104857 · Cited by 283
Self-citationOlanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial
Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18101125 · Cited by 211
Himmerich, H., Kan, C., Au, K., & Treasure, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107667 · Cited by 137
Self-citationPsychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Self-citation
Metadata
- Authors
- Dold, M., Aigner, M., Klabunde, M., Treasure, J., & Kasper, S.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 84
- Issue
- 2
- Pages
- 110-116
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2017437419
- Cited by
- 86
- References
- 11
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.